Loading
NASDAQHealthcareBiotechnology
Latest quote
$218.29
−$12.90 · -5.58%
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Regular session
$218.29
−$12.90 · -5.58%
Regular session · ET · Market data may be delayed.
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Day range
Current $218.29
52-week range
Current $218.29
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
54
Fair Value
Sentiment
57
Mixed
Risk
17
Low Risk
Momentum
66
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Day range
Current $218.29
52-week range
Current $218.29
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 4.27B USD | 4.07B USD | 3.83B USD | 3.66B USD | 3.09B USD |
| Cost of goods sold | 503.3M USD | 445.71M USD | 435.58M USD | 540.52M USD | 440.76M USD |
| Gross profit | 3.76B USD | 3.62B USD | 3.4B USD | 3.12B USD | 2.65B USD |
| Research and development | 782.74M USD | 884M USD | 849.66M USD | 590.45M USD | 505.75M USD |
| Selling, general, and administrative | 1.81B USD | 1.39B USD | 1.34B USD | 1.42B USD | 1.45B USD |
| Operating expenses | 3.54B USD | 2.91B USD | 2.82B USD | 3.18B USD | 2.48B USD |
| Interest expense | 195.05M USD | 238.1M USD | 289.44M USD | 288.24M USD | 278.77M USD |
| Depreciation and amortization | 696.3M USD | 660.07M USD | 638.7M USD | 629.47M USD | 552.48M USD |
| Operating income | 224.42M USD | 716.63M USD | 578.58M USD | −65.53M USD | 170.28M USD |
| Net income | −356.15M USD | 560.12M USD | 414.83M USD | −224.06M USD | −328.95M USD |
Company facts updated Oct 8, 2026.
Third-party consensus; not a GoAI recommendation.
Average target
$293
34.23% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI474.41M0.02%2.3T USD0.03%$379.48-0.41%
Vanguard Morningstar Small-Cap ETFVB343.72M0.18%185.3B USD0.03%$284.85-0.74%
Vanguard Morningstar Small-Cap Value ETFVBR218.34M0.32%68.2B USD0.05%$230.77-0.61%
Vanguard Extended Market ETFVXF182.67M0.19%95.4B USD0.05%$231.38-0.90%
Invesco S&P MidCap Momentum ETFXMMO162.05M2.23%7.25B USD0.34%$147.53-0.54%
VictoryShares Free Cash Flow ETFVFLO151.91M1.36%11.19B USD0.44%$52.235-0.09%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY111.23M0.43%25.98B USD0.23%$660.49-0.52%
State Street SPDR Portfolio S&P 400 Mid Cap ETFSPMD79.69M0.43%18.47B USD0.03%$63.415-0.54%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Value ETFVBRVanguard Extended Market ETFVXFInvesco S&P MidCap Momentum ETFXMMOVictoryShares Free Cash Flow ETFVFLOState Street SPDR S&P MIDCAP 400 ETF TrustMDYState Street SPDR Portfolio S&P 400 Mid Cap ETFSPMDAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
